OpGen (OPGN) 10-Q 15 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-37367
Entity Registrant Name	OPGEN, INC.
Entity Central Index Key	0001293818
Entity Tax Identification Number	06-1614015
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	23219 Stringtown Road
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Clarksburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20871
City Area Code	240
Local Phone Number	813-1260
Title of 12(b) Security	Common Stock
Trading Symbol	OPGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,068,111

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,633,166	$ 1,151,823
Accounts receivable, net	24,401	103,316
Prepaid expenses and other current assets	1,559,786	324,735
Total current assets	3,217,353	1,579,874
Property and equipment, net	1,117,245
Finance lease right-of-use assets, net		138
Operating lease right-of-use assets	832,966
Other noncurrent assets	302,262	302,262
Total assets	5,469,826	1,882,274
Current liabilities
Accounts payable	103,868	111,149
Accrued compensation and benefits	49,146	127,601
Accrued liabilities	89,173	135,476
Deferred revenue		25,926
EIB loan guaranty		10,873,867
Short-term insurance financing	180,555
Short-term finance lease liabilities		280
Short-term operating lease liabilities	167,021	147,943
Total current liabilities	589,763	11,422,242
Long-term operating lease liabilities, net of short-term amount	1,893,794	2,021,616
Total liabilities	2,483,557	13,443,858
Stockholders’ equity (deficit)
Common stock, $0.01 par value; 100,000,000 shares authorized; 10,068,111 and 1,282,686 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	100,681	12,827
Additional paid-in capital	300,736,192	293,991,529
Accumulated deficit	(297,850,606)	(305,493,302)
Accumulated other comprehensive loss		(75,138)
Total stockholders’ equity (deficit)	2,986,269	(11,561,584)
Total liabilities and stockholders’ equity	5,469,826	1,882,274
Preferred Stock Series D [Member]
Stockholders’ equity (deficit)
Preferred stock, value	$ 2	$ 2,500

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, shares authorized	10,000,000
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	10,068,111	1,282,686
Common stock, shares issued	10,068,111	1,282,686
Preferred Stock Series D [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	250	250
Preferred stock, shares outstanding	250	250

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue
Total revenue		$ 699,022	$ 196,149	$ 2,348,601
Operating expenses
Cost of products sold		618,796	31,636	1,925,566
Cost of services		73,174	1,575	405,582
Research and development, net	488	1,201,865	49,308	4,403,488
General and administrative	768,551	2,034,628	4,021,321	6,883,588
Sales and marketing	14,846	336,184	168,819	2,522,471
Total operating expenses	783,885	4,264,647	4,272,659	16,140,695
Operating loss	(783,885)	(3,565,625)	(4,076,510)	(13,792,094)
Other income (expense)
Interest and other income	92,131	24,977	242,799	86,301
Interest expense	(3,238)	(396,768)	(4,317)	(1,698,564)
Gain on impairment adjustment			2,079,575
Gain on extinguishment of debt	9,738,487		9,738,487
Gain on settlement of compensation expenses	570,785		570,785
Foreign currency transaction (losses) gains	(2)	(135,930)	463	(288,326)
Change in fair value of derivative financial instruments		10,389		65,800
Change in fair value of EIB loan guaranty	(683,200)		(908,586)
Total other income (expense)	9,714,963	(497,332)	11,719,206	(1,834,789)
Income (loss) before income taxes	8,931,078	(4,062,957)	7,642,696	(15,626,883)
Provision for income taxes
Net income (loss)	8,931,078	(4,062,957)	7,642,696	(15,626,883)
Net income (loss) allocated to preferred stockholders – basic	(690,467)		(519,161)
Net income (loss) available to common stockholders – basic	8,240,611	(4,062,957)	7,123,535	(15,626,883)
Net income (loss)	8,931,078	(4,062,957)	7,642,696	(15,626,883)
Net income (loss) allocated to preferred stockholders – diluted
Net income (loss) available to common stockholders – diluted	$ 8,931,078	$ (4,062,957)	$ 7,642,696	$ (15,626,883)
Earnings (loss) per share attributable to common stockholders
Basic	$ 1.43	$ (4.63)	$ 2.51	$ (23.80)
Diluted	$ 1.35	$ (4.63)	$ 2.14	$ (23.80)
Weighted average shares outstanding
Basic	5,760,214	877,815	2,837,744	656,585
Diluted	6,603,804	877,815	3,571,505	656,585
Other comprehensive income – foreign currency translation		$ 78,815		$ 118,178
Comprehensive income (loss)	8,931,078	(3,984,142)	7,642,696	(15,508,705)
Product [Member]
Revenue
Total revenue		558,965	169,373	1,409,534
Service [Member]
Revenue
Total revenue		47,135	26,776	112,810
Collaborations Revenue [Member]
Revenue
Total revenue		$ 92,922		$ 826,257

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022	$ 2,900		$ 281,193,260	$ (795,840)	$ (272,824,772)	$ 7,575,548
Beginning balance, shares at Dec. 31, 2022	289,992
Issuance of RSUs	$ 12		(12)
Issuance of RSUs, shares	1,163
Stock compensation expense			211,122			211,122
Offering of common stock and warrants, net of issuance costs	$ 2,586		6,971,464			6,974,050
Offering of common stock and warrants, net of issuance costs, shares	258,621
Share cancellation	$ (2)		2
Share cancellation, shares	(220)
Foreign currency translation				153,067		153,067
Net income					(5,736,603)	(5,736,603)
Ending balance, value at Mar. 31, 2023	$ 5,496		288,375,836	(642,773)	(278,561,375)	9,177,184
Ending balance, shares at Mar. 31, 2023	549,556
Issuance of RSUs	$ 22		(22)
Issuance of RSUs, shares	2,216
Stock compensation expense			156,529			156,529
Cash bonus taken in the form of stock compensation			283,554			283,554
Offering of common stock and warrants, net of issuance costs	$ 1,450		3,182,200			3,183,650
Offering of common stock and warrants, net of issuance costs, shares	145,000
Foreign currency translation				(113,704)		(113,704)
Net income					(5,827,323)	(5,827,323)
Ending balance, value at Jun. 30, 2023	$ 6,968		291,998,097	(756,477)	(284,388,698)	6,859,890
Ending balance, shares at Jun. 30, 2023	696,772
Stock compensation expense			(229,483)			(229,483)
Offering of common stock and warrants, net of issuance costs	$ 3,046		27,412			30,458
Offering of common stock and warrants, net of issuance costs, shares	304,583
Foreign currency translation				78,815		78,815
Net income					(4,062,957)	(4,062,957)
Ending balance, value at Sep. 30, 2023	$ 10,014		291,796,026	(677,662)	(288,451,655)	2,676,723
Ending balance, shares at Sep. 30, 2023	1,001,355
Beginning balance, value at Dec. 31, 2023	$ 12,827	$ 2,500	293,991,529	(75,138)	(305,493,302)	(11,561,584)
Beginning balance, shares at Dec. 31, 2023	1,282,686	250
Issuance of RSUs	$ 210		(210)
Issuance of RSUs, shares	21,053
Stock compensation expense			188,237			188,237
Offering of preferred stock		$ 2,000	198,000			200,000
Offering of preferred stock, shares		200,000
Reclassification of preferred stock par value to additional paid-in capital (out of period adjustment; see Note 3)		$ (2,498)	2,498
Elimination of translation adjustments of previously dissolved subsidiaries (out of period adjustment; see Note 3)				75,138		75,138
Net income					287,967	287,967
Ending balance, value at Mar. 31, 2024	$ 13,037	$ 2,002	294,380,054		(305,205,335)	(10,810,242)
Ending balance, shares at Mar. 31, 2024	1,303,739	200,250
Issuance of RSUs	$ 400		(400)
Issuance of RSUs, shares	40,000
Stock compensation expense			368,391			368,391
Share issuance related to May 2024 Reverse Stock Split	$ 53		(53)
Share issuance related to Reverse Stock Split, shares	5,238
Share cancellation related to May 2024 Reverse Stock Split
[custom:ShareCancellationRelatedtoReverseStockSplitShares]	(3)
Offering of preferred stock		$ 3,500	346,500			350,000
Offering of preferred stock, shares		350,000
Net income					(1,576,349)	(1,576,349)
Ending balance, value at Jun. 30, 2024	$ 13,490	$ 5,502	295,094,492		(306,781,684)	(11,668,200)
Ending balance, shares at Jun. 30, 2024	1,348,974	550,250
Stock compensation expense			1,530			1,530
Cash compensation taken in the form of stock compensation	$ 4,400		1,328,885			1,333,285
Cash compensation taken in the form of stock compensation, shares	440,028
Offering of preferred stock		$ 24,500	2,375,717			2,400,217
Offering of preferred stock, shares		2,450,000
Conversion of preferred stock into common stock	$ 72,000	$ (30,000)	(42,000)
Conversion of preferred stock into common stock, shares	7,200,000	(3,000,000)
Issuance of common stock pursuant to equity line of credit	$ 10,791		1,977,568			1,988,359
Issuance of common stock pursuant to equity line of credit, shares	1,079,109
Net income					8,931,078	8,931,078
Ending balance, value at Sep. 30, 2024	$ 100,681	$ 2	$ 300,736,192		$ (297,850,606)	$ 2,986,269
Ending balance, shares at Sep. 30, 2024	10,068,111	250

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net income (loss)	$ 7,642,696	$ (15,626,883)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation and amortization	129,502	1,070,581
Noncash interest expense		1,261,495
Stock compensation expense	558,158	138,168
Change in inventory reserve	(54,830)	535,755
Cash bonus taken in the form of stock compensation		283,554
Gain on impairment adjustment	(2,079,575)
Gain on settlement of compensation expenses	(570,785)
Loss on deconsolidation of subsidiaries	75,138
Change in fair value of derivative liabilities		(65,800)
Change in fair value of EIB loan guaranty	(10,873,867)
Changes in operating assets and liabilities
Accounts receivable	78,915	91,522
Inventory	54,830	290,366
Other assets	98,233	86,516
Accounts payable	(7,281)	399,197
Accrued compensation and other liabilities	337,284	(1,161,958)
Deferred revenue	(25,926)	54,388
Net cash used in operating activities	(4,637,508)	(12,643,099)
Cash flows from investing activities
Purchases of property and equipment		(799,498)
Net cash used in investing activities		(799,498)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs		10,188,158
Proceeds from issuance of preferred stock, net of issuance costs	2,950,217
Proceeds from issuance of common stock, net of issuance costs	1,988,359
Proceeds from short-term insurance financing	300,926
Payments on short-term insurance financing	(120,371)
Payments on debt		(3,910,010)
Payments on finance lease obligations	(280)	(2,523)
Net cash provided by financing activities	5,118,851	6,275,625
Effects of exchange rates on cash		15,977
Net increase (decrease) in cash and cash equivalents and restricted cash	481,343	(7,150,995)
Cash and cash equivalents and restricted cash at beginning of period	1,454,085	7,935,659
Cash and cash equivalents and restricted cash at end of period	1,935,428	784,664
Supplemental disclosure of cash flow information
Cash paid for interest	4,317	1,422,343
Supplemental disclosures of noncash investing and financing activities
Right-of-use assets acquired through operating leases		801,321
Purchased equipment not yet paid for		94,784
Settlement of deferred compensation and severance	1,333,285
Issuance of common stock upon conversion of preferred stock	$ 2,950,217

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 8,931,078	$ (4,062,957)	$ 7,642,696	$ (15,626,883)

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization

Organization	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1 – Organization OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. In April 2020, OpGen completed a business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, pursuant to which the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”), and certain other assets and liabilities of Curetis N.V., including Ares Genetics GmbH (“Ares Genetics”), a wholly owned subsidiary of Curetis GmbH (together, “Curetis”). From inception until November 2023, OpGen operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. In November 2023, Curetis filed a petition for insolvency with the district court of Stuttgart, Germany, and Ares Genetics filed a petition for insolvency with the commercial court in Vienna, Austria. The insolvency proceedings of Curetis and Ares Genetics were adjudicated under the insolvency laws of Germany and Austria, respectively. The insolvency administrators assumed control over the assets and liabilities of Curetis and Ares Genetics, respectively, which eliminated the authority and power of the Company and its officers to act on behalf of the subsidiaries. The loss of control required that the Company no longer include Curetis and Ares Genetics in its consolidated financial statements. Prior to the insolvency filings, Curetis and Ares Genetics had been included in the Company’s consolidated financial statements. As part of the insolvency proceedings, in April 2024, the insolvency administrator for Curetis notified the Company that all of Curetis’ assets were sold to Camtech Pte Ltd., a Singaporean family office (“Camtech”) In March 2024, the Company entered into a securities purchase agreement (the “March 2024 Purchase Agreement”) with David E. Lazar, pursuant to which the Company agreed to sell 3,000,000 1.00 3.0 in April 2024, the Company entered into an employment agreement with David E. Lazar, pursuant to which the Company engaged Mr. Lazar to act as its Chief Executive Officer (“CEO”). In April 2024, the Company entered into a lease assignment agreement where the Company assigned the lease of its Rockville, Maryland headquarters to a third party. The Company’s security deposit remains with the landlord and will be repaid over time as agreed upon with the third party assignee. The Company has a continuing liability under the lease; however, within the lease assignment agreement, the new tenant indemnifies the Company from and against any liabilities resulting from obligations arising on or after the lease assignment date. In May 2024, the Company announced that it intended to effect a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock, par value $0.01 per share (the “Common Stock”), at a ratio of 1 post-reverse-split share for every 10 pre-reverse-split shares (the “Reverse Split Ratio”). The Common Stock continued to be traded on The Nasdaq Capital Market under the symbol “OPGN” and began trading on a split-adjusted basis when the markets opened on Monday, May 20, 2024, under a new CUSIP number, 68373L505. The Reverse Stock Split impacted all holders of OpGen’s common stock proportionally and did not impact any stockholders’ percentage ownership of common stock (except to the extent the Reverse Stock Split resulted in any stockholder owning a fractional share). No fractional shares were issued in connection with the Reverse Stock Split. Stockholders of record who were otherwise entitled to receive a fractional share received a whole share in lieu of the fractional share. All share amounts and per share prices in this Quarterly Report have been adjusted to reflect the Reverse Stock Split. In July 2024, Mr. Lazar consummated a transaction pursuant to which he sold 550,000 AEI Capital Ltd. paid the Company $ 2.45 2,450,000 3,000,000 7,200,000 no Under the ownership of AEI Capital Ltd., the Company plans to continue scaling down legacy operations and selling the remaining Unyvero assets in inventory with the intention of exiting the Unyvero business. Going forward, the Company is planning to reposition itself and will launch a new business in the financial technology industry supporting digital investment banking activities. The Company also contemplates engaging in the provision of listing consultancy services to international companies seeking to list their securities on securities exchanges. The Company’s headquarters and principal operations were located at 9717 Key West Avenue, Suite 100, in Rockville, Maryland, through the end of the first quarter of 2024. Upon assignment of the Company’s lease, the Company operates virtually. The Company operates in one business segment.

Going Concern and Management_s

Going Concern and Management’s Plans	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 – Going Concern and Management’s Plans The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations and negative operating cash flows. Historically, the Company has funded its operations primarily through external investor financing arrangements and significant actions taken by the Company, but going forward, the Company anticipates funding its operations primarily through financing arrangements with AEI Capital Ltd. Through the Company’s financing efforts, which include, among others, securities purchase agreements, warrant inducement agreements, and public offerings, the Company has received gross proceeds of approximately $ 13.3 5.0 Although the Company only has cash and cash equivalents of $1.6 1,633,166 9.0 1,079,109 2.0 0.01 7.0 On June 5, 2024, the Company received a letter from the listing staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $ 2,500 The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of presentation and consolidation The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2023 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures, including notes required by GAAP, for complete financial statements. The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen as of and for the three and nine months ended September 30, 2024. All intercompany transactions and balances have been eliminated. Foreign currency In prior years, the Company had foreign operating subsidiaries, each of which use currencies other than the U.S. dollar as their functional currency. As a result, all assets and liabilities of the subsidiaries were translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items were translated at the average exchange rates prevailing during the reporting period. Translation adjustments were reported in accumulated other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments were the sole component of accumulated other comprehensive income (loss) at December 31, 2023. Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net income (loss). Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar. Immaterial Out of Period Adjustments During the three months ended March 31, 2024, the Company identified an immaterial error related to the calculation of preferred stock par value and additional paid-in capital for the Company’s Series D convertible preferred stock that impacted the Company’s previously issued 2023 consolidated financial statements. Management evaluated the effect of the error on the 2023 and current period consolidated financial statements and concluded the error was not material. As a result, in the three months ended March 31, 2024, the Company recorded an out of period adjustment to decrease preferred stock par value and increase additional paid-in capital, each by approximately $ 2.5 During the three months ended March 31, 2024, the Company identified an immaterial error related to the inclusion of balances of accumulated other comprehensive loss representing historic translation adjustments of previously dissolved subsidiaries that impacted the Company’s previously issued 2023 and 2022 consolidated financial statements. Management evaluated the effect of the error on the 2023, 2022, and current period consolidated financial statements and concluded the error was not material. As a result, in the three months ended March 31, 2024, the Company recorded an out of period adjustment to increase the loss on deconsolidation of subsidiaries and decrease accumulated other comprehensive loss, each by approximately $ 75.1 75,138 Restatement of Prior Period Financial Statements Subsequent to the filing of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, the Company identified an error relating to the accounting treatment of an indemnification asset in the Company’s previously issued unaudited condensed consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Affected Period”). As a result, the Company filed an amended Form 10-Q for the quarterly period ended March 31, 2024 to correct the error in the Affected Period by adjusting the following information for the three months ended March 31, 2024: (i) removing the previously recorded indemnification asset and gain on lease indemnification; and (ii) changing the accounting estimates related to the Company’s operating lease right-of-use asset and leasehold improvement property and equipment and recording a gain on impairment adjustment associated with the Rockville, Maryland office due to the identification of a subtenant in the three months ended March 31, 2024. In total, the restatement and associated change in accounting estimates resulted in an incremental loss of approximately $ 0.1 Use of estimates In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, property and equipment, lease right-of-use assets, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, and deferred tax assets and liabilities and related valuation allowance. Actual results could differ from those estimates. Fair value of financial instruments Financial instruments classified as current assets and liabilities (including cash and cash equivalents, receivables, accounts payable, and deferred revenue) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. Cash and cash equivalents and restricted cash The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the Federal Deposit Insurance Corporation (“FDIC”) insured limit of $ 250,000 At September 30, 2024 and December 31, 2023, the Company had funds totaling $ 302,262 The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets: Schedule of reconciliation of cash, cash equivalents and restricted cash September 30, December 31, Cash and cash equivalents $ 1,633,166 $ 1,151,823 Restricted cash 302,262 302,262 Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows $ 1,935,428 $ 1,454,085 Accounts receivable The Company’s accounts receivable result from amounts invoiced but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 90 0 At September 30, 2024, the Company had accounts receivable from one customer that individually represented 92% 39% 26% 10% 21% 15% 12% 11% 48% 14% 28% 17% 10% Inventory Inventories are valued using the first-in, first-out cost method and stated at the lower of cost or net realizable value and consist of the following: Schedule of inventories September 30, December 31, Finished goods $ 1,225,975 $ 1,280,805 Total, gross 1,225,975 1,280,805 Less inventory reserve (1,225,975 ) (1,280,805 ) Total, net of inventory reserve $ - $ - Inventory is entirely made up of Unyvero system instruments and components. The Company periodically reviews inventory quantities on hand and analyzes the provision for excess and obsolete inventory based primarily on product expiration dating and its estimated sales forecast, which is based on sales history and anticipated future demand. The Company’s estimates of future product demand may not be accurate, and it may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of the Company’s inventory and results of operations. Based on the Company’s assumptions and estimates, inventory reserves for obsolescence, expirations, and slow-moving inventory were $ 1,225,975 1,280,805 Long-lived assets Property and equipment Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2024 and 2023, the Company determined that its property and equipment was not impaired. Leases The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases. ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used are measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of the assets exceeds the fair value of the assets. The Company did no Intangible assets Intangible assets consist of finite-lived and indefinite-lived intangible assets. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. All the Company’s finite-lived intangible assets with net balances were held by Curetis and Ares Genetics. As a result of the insolvency filings for Curetis and Ares Genetics and the associated deconsolidation of all balance sheet balances related to these entities in 2023, the Company does not have any finite-lived or indefinite-lived intangible asset balances as of September 30, 2024. Total amortization expense of intangible assets was $ 0 187,255 Revenue recognition During the nine months ended September 30, 2024 and 2023, the Company derived revenues from (i) the sale of Unyvero Application cartridges, Unyvero Systems, Acuitas AMR Gene Panel systems and test products, and SARS CoV-2 tests, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, license arrangements, and its NGO collaboration with the Foundation for Innovative New Diagnostics (FIND) on our Unyvero A30 platform. The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented. Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided. Government grant agreements and research incentives From time to time, the Company may enter into arrangements with governmental entities for the purposes of obtaining funding for research and development activities. The Company recognized funding from grants and research incentives received from Austrian government agencies in the condensed consolidated statements of operations and comprehensive loss in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. The Company classifies government grants received under these arrangements as a reduction to the related research and development expense incurred. The Company analyzes each arrangement on a case-by-case basis. For the three and nine months ended September 30, 2023, the Company recognized $ 78,752 301,229 no Research and development costs, net Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, and fees paid to consultants and outside service partners. Stock-based compensation Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the award. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own ordinary shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% The Company had federal net operating loss (“NOL”) carryforwards of $ 241,110,447 232,682,072 Net income (loss) per share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series D and Series E convertible preferred stock contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the preferred stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. In periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the preferred stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury stock method” are calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and preferred stock using the if-converted method. The Company has calculated basic and diluted earnings (loss) per share for the three months ended September 30, 2024 and 2023 as follows: Schedule of earnings per share, basic and diluted Basic Diluted Three months ended Three months ended September 30, September 30, 2023 September 30, 2024 September 30, Net income (loss) $ 8,931,078 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Net income allocated to preferred stockholders (690,467 ) - - - Net income (loss) available to common stockholders $ 8,240,611 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Basic weighted average shares outstanding 5,760,214 877,815 5,760,214 877,815 Dilutive effect of preferred stock 843,590 - Dilutive weighted average shares outstanding 6,603,804 877,815 Earnings (loss) per share $ 1.43 $ (4.63 ) $ 1.35 $ (4.63 ) The Company has calculated basic and diluted earnings (loss) per share for the nine months ended September 30, 2024 and 2023 as follows: Basic Diluted Nine months ended Nine months ended September 30, September 30, September 30, September 30, Net income (loss) $ 7,642,696 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Net income allocated to preferred stockholders (519,161 ) - - - Net income (loss) available to common stockholders $ 7,123,535 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Basic weighted average shares outstanding 2,837,744 656,585 2,837,744 656,585 Dilutive effect of preferred stock 733,761 - Dilutive weighted average shares outstanding 3,571,505 656,585 Earnings (loss) per share $ 2.51 $ (23.80 ) $ 2.14 $ (23.80 ) The number of anti-dilutive shares for the three and nine months ended September 30, 2024 and 2023, consisting of shares of common stock underlying (i) common stock options, (ii) restricted stock units, (iii) preferred stock, and (iv) stock purchase warrants, which have been excluded from the computation of diluted income per share was 1.2 1.1 Recently issued accounting standards The Company has evaluated all issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Revenue from contracts with cus

Revenue from contracts with customers	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from contracts with customers	Note 4 – Revenue from contracts with customers Disaggregated revenue The Company provided diagnostic test products and laboratory services to hospitals, clinical laboratories and other healthcare providing customers, and entered into collaboration agreements with government agencies, non-governmental organizations, and healthcare providers. The revenues by type of service consist of the following: Schedule of revenues by type of service Three Months Ended Nine Months Ended 2024 2023 2024 2023 Product sales $ - $ 558,965 $ 169,373 $ 1,409,534 Laboratory services - 47,135 26,776 112,810 Collaboration revenue - 92,922 - 826,257 Total revenue $ - $ 699,022 $ 196,149 $ 2,348,601 Revenues by geography are as follows: Schedule of revenues by geography Three Months Ended Nine Months Ended 2024 2023 2024 2023 Domestic $ - $ 142,716 $ 196,149 $ 523,978 International - 556,306 - 1,824,623 Total revenue $ - $ 699,022 $ 196,149 $ 2,348,601 Deferred revenue Changes to deferred revenue for the periods were as follows: Schedule of changes in deferred revenue Balance at December 31, 2022 $ 142,061 Contracts with customers 74,109 Recognized in the current period (144,196 ) Currency translation adjustment (46,048 ) Balance at December 31, 2023 25,926 Recognized in the current period (21,096 ) Refunded to customers in the current period (4,830 ) Balance at September 30, 2024 $ -

Fair value measurements

Fair value measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair value measurements	Note 5 – Fair value measurements The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: ● Level 1 - defined as observable inputs such as quoted prices in active markets; ● Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and ● Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections. For the three and nine months ended September 30, 2024, the Company has not transferred any assets between fair value measurement levels. Financial assets and liabilities measured at fair value on a recurring basis The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. In 2016, Curetis entered into a contract for an up to € 25.0 5.0 15.0 5.0 2.1% 2.1% 5.0 2.1% 0.3% the Company entered into a Waiver and Amendment Letter which increased the PPI to 0.75% Following Curetis’ insolvency filing, in November 2023, Curetis received a termination notice from the EIB terminating the Standstill Agreement, pursuant to which the EIB had agreed that the EIB would not take any action or exercise any right with respect to an event of default under the Finance Contract, effective as of November 20, 2023. In December 2023, the Company received a notice from the EIB stating that Curetis was in default of the Finance Contract as a result of, among other things, Curetis’ failure to repay when due certain outstanding indebtedness under the Finance Contract. Pursuant to that certain Guarantee and Indemnity Agreement, dated July 9, 2020, between the EIB and the Company, the EIB demanded that the Company, as guarantor, immediately repay the EIB all amounts owed to the EIB under the Finance Contract and reserved all its other rights and remedies in connection with the Finance Contract. The Company determined the fair value of the PPI using the Monte Carlo simulation model as of August 19, 2024, the date in which the Company paid and settled its outstanding indebtedness with the EIB. Upon settlement of such indebtedness, the Company recorded a gain on extinguishment of debt of approximately $ 9.7 Financial assets and liabilities carried at fair value on a non-recurring basis The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis. Non-financial assets and liabilities carried at fair value on a recurring basis The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis. Non-financial assets and liabilities carried at fair value on a non-recurring basis The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when a triggering event requires such evaluation. During the three and nine months ended September 30, 2024, the Company did not record any such impairment expenses.

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Note 6 – Debt The following table summarizes the Company’s EIB loan guaranty as of September 30, 2024 and December 31, 2023, which loan was paid off and settled in August 2024: Schedule of EIB loan guaranty September 30, 2024 December 31, EIB $ - $ 10,873,867 Total obligations - 10,873,867 Unamortized discount - - Carrying value of EIB loan guaranty - 10,873,867 Less EIB loan guaranty (current portion) - (10,873,867 ) Long-term EIB loan guaranty $ - $ - EIB Loan Facility In 2016, Curetis entered into a contract for an up to € 25.0 36 5 In April 2017, Curetis drew down a first tranche of € 10.0 4% 6% 3.0 5.0 15.0 5.0 2.1% 2.1% 5.0 0.3% 15.8 In May 2022, the Company and the EIB entered into a Waiver and Amendment Letter (the “2022 EIB Amendment”) relating to the amendment of the EIB loan facility, between the EIB and Curetis, pursuant to which Curetis borrowed an aggregate amount of € 18.0 13.4 5.0 0.7 0.3% 0.75% 3.0 5.0 In June 2023, the Company announced that its subsidiary Curetis and the European Investment Bank (“EIB”) agreed in principle to certain terms relating to the repayment of the second tranche of Curetis’ loan from the EIB pursuant to that certain Finance Contract, dated December 12, 2016, as amended, by and between Curetis and the EIB (the “Finance Contract”). The second tranche had a principal balance of € 3 1 In November 2023, Curetis received a termination notice from the EIB terminating the Standstill Agreement effective as of November 20, 2023. The EIB’s termination notice stated that the termination of the Standstill Agreement was as a result of and in connection with certain defaults of the Standstill Agreement arising from, among other related reasons, Curetis’ and Ares’ entry into insolvency proceedings. In December 2023, the Company received a notice from the EIB stating that Curetis was in default of the Finance Contract as a result of, among other things, Curetis’ failure to repay when due certain outstanding indebtedness under the Finance Contract. In its notice, the EIB stated that, as of November 16, 2023, the aggregate amount of principal, accrued interest and all other amounts owed by Curetis to the EIB under the Finance Contract was approximately €9.66 million and that interest will continue to accrue in accordance with the Finance Contract until all amounts owed are paid in full. Pursuant to that certain Guarantee and Indemnity Agreement, dated July 9, 2020 (the “Guaranty”), between the EIB and the Company, the EIB demanded that the Company, as guarantor, immediately repay the EIB all amounts owed to the EIB under the Finance Contract and reserved all of its other rights and remedies in connection with the Finance Contract. In connection with the Company’s entry into the March 2024 Purchase Agreement with David E. Lazar in March 2024, the Company entered into settlement agreements with each of the EIB and Curetis and Curetis’ trustee in insolvency, pursuant to which the Company agreed to pay a total of $2.0 million to settle all outstanding debt and liabilities of the Company to EIB and Curetis. The settlement agreement with EIB also provided for the termination of that certain Guarantee and Indemnity Agreement, dated as of July 9, 2020, by and between the EIB and the Company, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. On August 19, 2024, the Company paid and settled its outstanding indebtedness with the EIB and Curetis, which terminated the Guarantee and Indemnity Agreement. Accordingly, upon termination of such Guarantee and Indemnity Agreement, the Company recorded a gain on extinguishment of debt in excess of $ 9.7 Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $ 3,238 396,768 4,317 1,698,564 In May 2024, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $ 300,926 31,172 7.75%

Stockholders_ equity

Stockholders’ equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ equity	Note 7 – Stockholders’ equity As of September 30, 2024, the Company had 100,000,000 shares of authorized common stock and 10,068,111 10,000,000 6,999,000 Following receipt of approval from stockholders at a special meeting of stockholders held in November 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty shares, and the reverse stock split was effective January 5, 2023. All share amounts and per share prices in this Quarterly Report have been adjusted to reflect the reverse stock split. Following receipt of approval from stockholders at a special meeting of stockholders held in May 2024, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for ten shares, and the reverse stock split was effective May 20, 2024. All share amounts and per share prices in this Quarterly Report have been adjusted to reflect the reverse stock split. In January 2023, the Company closed a best-efforts public offering pursuant to a securities purchase agreement with a certain institutional investor for the purchase of (i) 32,121 shares of the Company’s common stock, par value $0.01 per share, (ii) pre-funded warrants to purchase up to an aggregate of 226,500 258,621 258,621 29.00 28.90 7.5 6.9 26.50 0.10 7.785 In May 2023, the Company closed a best-efforts public offering pursuant to a securities purchase agreement with a certain institutional investor, pursuant to which the Company issued and sold to the investor (i) 60,500 0.01 389,083 449,583 7.785 7.685 3.5 3.0 7.785 0.25 0.10 639,691 26.50 75.40 0.3 , the holder exercised 200,000 2.057 In October 2023, the Company entered into a Preferred Stock Purchase Agreement (the “October 2023 Purchase Agreement”) with a single investor, pursuant to which the Company agreed to issue and sell to the investor in a private placement (the “Private Placement”) 1,000 0.01 1,000 0.01 4.09 19.99% 250,000 750,000 In October 2023, the Company entered into a warrant inducement agreement (the “Inducement Agreement”) with a holder (the “Holder”) of certain existing warrants (the “Existing Warrants”) to purchase shares of common stock, par value $0.01 per share, of the Company. Pursuant to the Inducement Agreement, the Holder agreed to exercise for cash their Existing Warrants to purchase up to 1,089,274 7.785 0.25 100% , the Holder exercised 200,000 shares of Common Stock under the existing warrants pursuant to the Inducement Agreement for aggregate gross proceeds to the Company of $2.057 million before deducting financial advisory fees and other expenses payable by the Company. The Holder did not exercise any additional Existing Warrants prior to the termination of the April 30, 2024 extended offer period. In March 2024, the Company entered into a securities purchase agreement (the “March 2024 Purchase Agreement”) with David E. Lazar, pursuant to which the Company agreed to sell 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) to Mr. Lazar at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. In connection with the transactions contemplated by the March 2024 Purchase Agreement, the members of the Board of Directors, prior to the closing of such transactions, resigned and a new Board of Directors was appointed, of which Mr. Lazar was appointed Chairman. In March 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions under the March 2024 Purchase Agreement in exchange for 200,000 350,000 Each share of Series E Preferred Stock was convertible into 2.4 shares of the Company’s common stock in excess of applicable beneficial ownership limitations In July 2024, Mr. Lazar consummated a transaction pursuant to which he sold 550,000 Subsequently, 2.45 2,450,000 3,000,000 7,200,000 no In August 2024, the Company entered into a Securities Purchase Agreement (the “August 2024 Securities Purchase Agreement”) with AEI Capital Ltd., pursuant to which the Company had the right, in its discretion, to sell to AEI Capital Ltd., at any time prior to September 30, 2024, shares of common stock, par value $ 0.01 3.0 1,079,109 2.0 9.0 Stock options In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors. In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants. Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 271 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. 48,058 12,506 For the three and nine months ended September 30, 2024 and 2023, the Company recognized share-based compensation expense as follows: Schedule of company recognized stock compensation expense Three months ended Nine months ended 2024 2023 2024 2023 Cost of services $ - $ (442 ) $ - $ (442 ) Research and development - (159,742 ) 48,820 (41,914 ) General and administrative 1,530 74,411 504,941 259,452 Sales and marketing - (143,710 ) 4,397 (78,928 ) $ 1,530 $ (229,483 ) $ 558,158 $ 138,168 No income tax benefit for share-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company’s anticipated net taxable loss position for the year ended December 31, 2024. The Company did not grant any options during the three and nine months ended September 30, 2024. During the three months ended September 30, 2024, no 5,813 892 8,594 The Company had total stock options to acquire 138 Restricted stock units During the three months ended September 30, 2024, no no 61,053 61,053 4,163 4,163 Stock purchase warrants At September 30, 2024 and December 31, 2023, the following warrants to purchase shares of common stock were outstanding: Schedule of stock purchase warrants Outstanding at Issuance Exercise Price Expiration September 30, December 31, February 2015 $ 660,000.00 February 2025 3 3 October 2019 $ 400.00 October 2024 1,770 1,770 October 2019 $ 520.00 October 2024 1,175 1,175 November 2020 $ 504.40 May 2026 1,211 1,211 February 2021 $ 780.00 August 2026 2,084 2,084 May 2023 $ 7.785 (1) 889,274 889,274 October 2023 $ 3.36 April 2029 200,000 200,000 1,095,517 1,095,517 The warrants listed above were issued in connection with various equity, debt, or development contract agreements. (1) Warrants will be exercisable beginning on the date of stockholder approval of the exercisability of the warrants under Nasdaq rules. Once exercisable, the warrants will expire on the five-year anniversary of the date of such stockholder approval.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 – Commitments and Contingencies Registration and other stockholder rights In connection with various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company’s common stock.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 9 – Leases The following table presents the Company’s ROU assets and lease liabilities as of September 30, 2024 and December 31, 2023: Schedule of ROU asset and liability classifications Lease Classification September 30, December 31, ROU Assets: Operating $ 832,966 $ - Financing - 138 Total ROU assets $ 832,966 $ 138 Liabilities Current: Operating $ 167,021 $ 147,943 Finance - 280 Noncurrent: Operating 1,893,794 2,021,616 Finance - - Total lease liabilities $ 2,060,815 $ 2,169,839 Maturities of lease liabilities as of September 30, 2024 by fiscal year are as follows: Schedule of maturities of lease liabilities Maturity of Lease Liabilities Operating Finance Total 2024 (October to December) $ 90,395 $ - $ 90,395 2025 368,179 - 368,179 2026 378,279 - 378,279 2027 388,682 - 388,682 2028 399,388 - 399,388 Thereafter 1,338,299 - 1,338,299 Total lease payments 2,963,222 - 2,963,222 Less: Interest (902,407 ) - (902,407 ) Present value of lease liabilities $ 2,060,815 $ - $ 2,060,815 Condensed consolidated statements of operations classification of lease costs as of the three and nine months ended September 30, 2024 and 2023 are as follows: Schedule of lease cost Three months ended Nine months ended Lease Cost Classification 2024 2023 2024 2023 Operating Operating expenses $ 58,496 $ 175,243 $ 175,488 $ 484,546 Finance: Amortization Operating expenses - 847 138 2,514 Interest expense Other expenses - - - - Total lease costs $ 58,496 $ 176,090 $ 175,626 $ 487,060 Other lease information as of September 30, 2024 is as follows: Schedule of other information Other Information Total Weighted average remaining lease term (in years) Operating leases 7.4 Finance leases - Weighted average discount rate: Operating leases 10.0 % Finance leases - % Supplemental cash flow information as of the nine months ended September 30, 2024 and 2023 is as follows: Schedule of supplemental cash flow information Supplemental Cash Flow Information 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Cash used in operating activities Operating leases $ 175,488 $ 484,546 Finance leases $ - $ - Cash used in financing activities Finance leases $ 280 $ 2,523 ROU assets obtained in exchange for lease obligations: Operating leases $ - $ 801,321

License agreements, research co

License agreements, research collaborations and development agreements	9 Months Ended
	Sep. 30, 2024
License Agreements Research Collaborations And Development Agreements
License agreements, research collaborations and development agreements	Note 10 – License agreements, research collaborations and development agreements Sandoz In December 2018, Ares Genetics entered into a service frame agreement with Sandoz International GmbH (“Sandoz”) to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’s anti-infective portfolio. Under the terms of the framework agreement, which had an initial term of 36 months and was subsequently extended through January 2025, Ares Genetics and Sandoz intended to develop a digital anti-infectives platform, combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life-cycle management. The collaboration, in the short- to mid-term, aimed to both rapidly and cost-effectively re-purpose existing antibiotics and design value-added medicines with the objective of expanding indication areas and to overcome antibiotic resistance, in particular with regards to infections with bacteria that have already developed resistance against multiple treatment options. In the longer-term, the platform was expected to enable surveillance for antimicrobial resistant pathogens to inform antimicrobial stewardship and the development of novel anti-infectives that are less prone to encounter resistance and thereby preserve antibiotics as an effective treatment option. Following Ares Genetics’ insolvency filing in 2023, the Company will no longer benefit from this framework agreement. Qiagen In February 2019, Ares Genetics and Qiagen GmbH, or Qiagen, entered into a strategic licensing agreement for ARESdb and AREStools in the area of AMR research. The agreement had a term of 20 180 Under the terms of the original agreement, Qiagen, in exchange for a moderate six figure up-front licensing payment, received an exclusive RUO license to develop and commercialize general bioinformatics offerings and services for AMR research use only, based on Ares Genetics’ database on the genetics of antimicrobial resistance, ARESdb, as well as on the ARES bioinformatics AMR toolbox, AREStools. Under the agreement, the parties had agreed to a mid-single digit percentage royalty rate on Qiagen net sales, which is subject to a minimum royalty rate that steps up upon certain achieved milestones, which is payable to Ares Genetics. The parties also agreed to further modest six figure milestone payments upon certain product launches. The contract was subsequently amended in May 2021 to a non-exclusive license and a flat annual license fee as well as a royalty percentage on potential future panel-based products that are developed by Qiagen. Following the insolvency filings of Curetis and Ares Genetics in 2023, the Company will no longer benefit from this strategic licensing agreement. Siemens In 2016, Ares Genetics acquired the GEAR assets from Siemens Technology Accelerator GmbH (“STA”), providing the original foundation to ARESdb. Under the agreement with STA, Ares Genetics incurred royalties on revenues from licensed product sales or sublicensing proceeds. Royalty rates under the Siemens agreement ranged from 1.3% 40% 0 3,102 0 7,309 Foundation for Innovative New Diagnostics (FIND) In September 2022, Curetis GmbH and FIND entered into a research and development collaboration agreement for € 0.7 three and nine months ended September 30, 2024. The agreement-to-date revenue recognized by the Company related to the FIND collaboration was $ 0.9

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the unaudited condensed consolidated financial statements are issued. Other than as disclosed in this Note 11 and as may be disclosed elsewhere in the notes to the accompanying unaudited condensed consolidated financial statements, there have been no subsequent events that require adjustment or disclosure in the accompanying unaudited condensed consolidated financial statements. In October 2024, the Company and AEI Capital Ltd. entered into a First Amendment (the “Amendment”) to the August 2024 Securities Purchase Agreement. The Amendment amended the August 2024 Securities Purchase Agreement by: (1) granting the Company the right to sell two additional tranches of common stock to AEI Capital Ltd. of $3.0 million each, for an aggregate amount of $9.0 million under the August 2024 Securities Purchase Agreement; and (2) extending the Company’s ability to sell shares of common stock to AEI Capital Ltd. under the August 2024 Securities Purchase Agreement until December 31, 2025.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2023 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures, including notes required by GAAP, for complete financial statements. The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen as of and for the three and nine months ended September 30, 2024. All intercompany transactions and balances have been eliminated.
Foreign currency	Foreign currency In prior years, the Company had foreign operating subsidiaries, each of which use currencies other than the U.S. dollar as their functional currency. As a result, all assets and liabilities of the subsidiaries were translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items were translated at the average exchange rates prevailing during the reporting period. Translation adjustments were reported in accumulated other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments were the sole component of accumulated other comprehensive income (loss) at December 31, 2023. Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net income (loss). Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.
Immaterial Out of Period Adjustments	Immaterial Out of Period Adjustments During the three months ended March 31, 2024, the Company identified an immaterial error related to the calculation of preferred stock par value and additional paid-in capital for the Company’s Series D convertible preferred stock that impacted the Company’s previously issued 2023 consolidated financial statements. Management evaluated the effect of the error on the 2023 and current period consolidated financial statements and concluded the error was not material. As a result, in the three months ended March 31, 2024, the Company recorded an out of period adjustment to decrease preferred stock par value and increase additional paid-in capital, each by approximately $ 2.5 During the three months ended March 31, 2024, the Company identified an immaterial error related to the inclusion of balances of accumulated other comprehensive loss representing historic translation adjustments of previously dissolved subsidiaries that impacted the Company’s previously issued 2023 and 2022 consolidated financial statements. Management evaluated the effect of the error on the 2023, 2022, and current period consolidated financial statements and concluded the error was not material. As a result, in the three months ended March 31, 2024, the Company recorded an out of period adjustment to increase the loss on deconsolidation of subsidiaries and decrease accumulated other comprehensive loss, each by approximately $ 75.1 75,138
Restatement of Prior Period Financial Statements	Restatement of Prior Period Financial Statements Subsequent to the filing of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, the Company identified an error relating to the accounting treatment of an indemnification asset in the Company’s previously issued unaudited condensed consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Affected Period”). As a result, the Company filed an amended Form 10-Q for the quarterly period ended March 31, 2024 to correct the error in the Affected Period by adjusting the following information for the three months ended March 31, 2024: (i) removing the previously recorded indemnification asset and gain on lease indemnification; and (ii) changing the accounting estimates related to the Company’s operating lease right-of-use asset and leasehold improvement property and equipment and recording a gain on impairment adjustment associated with the Rockville, Maryland office due to the identification of a subtenant in the three months ended March 31, 2024. In total, the restatement and associated change in accounting estimates resulted in an incremental loss of approximately $ 0.1
Use of estimates	Use of estimates In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, property and equipment, lease right-of-use assets, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, and deferred tax assets and liabilities and related valuation allowance. Actual results could differ from those estimates.
Fair value of financial instruments	Fair value of financial instruments Financial instruments classified as current assets and liabilities (including cash and cash equivalents, receivables, accounts payable, and deferred revenue) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.
Cash and cash equivalents and restricted cash	Cash and cash equivalents and restricted cash The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the Federal Deposit Insurance Corporation (“FDIC”) insured limit of $ 250,000 At September 30, 2024 and December 31, 2023, the Company had funds totaling $ 302,262 The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets: Schedule of reconciliation of cash, cash equivalents and restricted cash September 30, December 31, Cash and cash equivalents $ 1,633,166 $ 1,151,823 Restricted cash 302,262 302,262 Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows $ 1,935,428 $ 1,454,085
Accounts receivable	Accounts receivable The Company’s accounts receivable result from amounts invoiced but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 90 0 At September 30, 2024, the Company had accounts receivable from one customer that individually represented 92% 39% 26% 10% 21% 15% 12% 11% 48% 14% 28% 17% 10%
Inventory	Inventory Inventories are valued using the first-in, first-out cost method and stated at the lower of cost or net realizable value and consist of the following: Schedule of inventories September 30, December 31, Finished goods $ 1,225,975 $ 1,280,805 Total, gross 1,225,975 1,280,805 Less inventory reserve (1,225,975 ) (1,280,805 ) Total, net of inventory reserve $ - $ - Inventory is entirely made up of Unyvero system instruments and components. The Company periodically reviews inventory quantities on hand and analyzes the provision for excess and obsolete inventory based primarily on product expiration dating and its estimated sales forecast, which is based on sales history and anticipated future demand. The Company’s estimates of future product demand may not be accurate, and it may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of the Company’s inventory and results of operations. Based on the Company’s assumptions and estimates, inventory reserves for obsolescence, expirations, and slow-moving inventory were $ 1,225,975 1,280,805
Long-lived assets	Long-lived assets Property and equipment Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2024 and 2023, the Company determined that its property and equipment was not impaired. Leases The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases. ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used are measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of the assets exceeds the fair value of the assets. The Company did no Intangible assets Intangible assets consist of finite-lived and indefinite-lived intangible assets. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. All the Company’s finite-lived intangible assets with net balances were held by Curetis and Ares Genetics. As a result of the insolvency filings for Curetis and Ares Genetics and the associated deconsolidation of all balance sheet balances related to these entities in 2023, the Company does not have any finite-lived or indefinite-lived intangible asset balances as of September 30, 2024. Total amortization expense of intangible assets was $ 0 187,255
Revenue recognition	Revenue recognition During the nine months ended September 30, 2024 and 2023, the Company derived revenues from (i) the sale of Unyvero Application cartridges, Unyvero Systems, Acuitas AMR Gene Panel systems and test products, and SARS CoV-2 tests, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, license arrangements, and its NGO collaboration with the Foundation for Innovative New Diagnostics (FIND) on our Unyvero A30 platform. The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented. Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.
Government grant agreements and research incentives	Government grant agreements and research incentives From time to time, the Company may enter into arrangements with governmental entities for the purposes of obtaining funding for research and development activities. The Company recognized funding from grants and research incentives received from Austrian government agencies in the condensed consolidated statements of operations and comprehensive loss in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. The Company classifies government grants received under these arrangements as a reduction to the related research and development expense incurred. The Company analyzes each arrangement on a case-by-case basis. For the three and nine months ended September 30, 2023, the Company recognized $ 78,752 301,229 no
Research and development costs, net	Research and development costs, net Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, and fees paid to consultants and outside service partners.
Stock-based compensation	Stock-based compensation Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the award. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own ordinary shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding.
Income taxes	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% The Company had federal net operating loss (“NOL”) carryforwards of $ 241,110,447 232,682,072
Net income (loss) per share	Net income (loss) per share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series D and Series E convertible preferred stock contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the preferred stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. In periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the preferred stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury stock method” are calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and preferred stock using the if-converted method. The Company has calculated basic and diluted earnings (loss) per share for the three months ended September 30, 2024 and 2023 as follows: Schedule of earnings per share, basic and diluted Basic Diluted Three months ended Three months ended September 30, September 30, 2023 September 30, 2024 September 30, Net income (loss) $ 8,931,078 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Net income allocated to preferred stockholders (690,467 ) - - - Net income (loss) available to common stockholders $ 8,240,611 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Basic weighted average shares outstanding 5,760,214 877,815 5,760,214 877,815 Dilutive effect of preferred stock 843,590 - Dilutive weighted average shares outstanding 6,603,804 877,815 Earnings (loss) per share $ 1.43 $ (4.63 ) $ 1.35 $ (4.63 ) The Company has calculated basic and diluted earnings (loss) per share for the nine months ended September 30, 2024 and 2023 as follows: Basic Diluted Nine months ended Nine months ended September 30, September 30, September 30, September 30, Net income (loss) $ 7,642,696 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Net income allocated to preferred stockholders (519,161 ) - - - Net income (loss) available to common stockholders $ 7,123,535 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Basic weighted average shares outstanding 2,837,744 656,585 2,837,744 656,585 Dilutive effect of preferred stock 733,761 - Dilutive weighted average shares outstanding 3,571,505 656,585 Earnings (loss) per share $ 2.51 $ (23.80 ) $ 2.14 $ (23.80 ) The number of anti-dilutive shares for the three and nine months ended September 30, 2024 and 2023, consisting of shares of common stock underlying (i) common stock options, (ii) restricted stock units, (iii) preferred stock, and (iv) stock purchase warrants, which have been excluded from the computation of diluted income per share was 1.2 1.1
Recently issued accounting standards	Recently issued accounting standards The Company has evaluated all issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of reconciliation of cash, cash equivalents and restricted cash	Schedule of reconciliation of cash, cash equivalents and restricted cash September 30, December 31, Cash and cash equivalents $ 1,633,166 $ 1,151,823 Restricted cash 302,262 302,262 Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows $ 1,935,428 $ 1,454,085
Schedule of inventories	Schedule of inventories September 30, December 31, Finished goods $ 1,225,975 $ 1,280,805 Total, gross 1,225,975 1,280,805 Less inventory reserve (1,225,975 ) (1,280,805 ) Total, net of inventory reserve $ - $ -
Schedule of earnings per share, basic and diluted	Schedule of earnings per share, basic and diluted Basic Diluted Three months ended Three months ended September 30, September 30, 2023 September 30, 2024 September 30, Net income (loss) $ 8,931,078 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Net income allocated to preferred stockholders (690,467 ) - - - Net income (loss) available to common stockholders $ 8,240,611 $ (4,062,957 ) $ 8,931,078 $ (4,062,957 ) Basic weighted average shares outstanding 5,760,214 877,815 5,760,214 877,815 Dilutive effect of preferred stock 843,590 - Dilutive weighted average shares outstanding 6,603,804 877,815 Earnings (loss) per share $ 1.43 $ (4.63 ) $ 1.35 $ (4.63 ) The Company has calculated basic and diluted earnings (loss) per share for the nine months ended September 30, 2024 and 2023 as follows: Basic Diluted Nine months ended Nine months ended September 30, September 30, September 30, September 30, Net income (loss) $ 7,642,696 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Net income allocated to preferred stockholders (519,161 ) - - - Net income (loss) available to common stockholders $ 7,123,535 $ (15,626,883 ) $ 7,642,696 $ (15,626,883 ) Basic weighted average shares outstanding 2,837,744 656,585 2,837,744 656,585 Dilutive effect of preferred stock 733,761 - Dilutive weighted average shares outstanding 3,571,505 656,585 Earnings (loss) per share $ 2.51 $ (23.80 ) $ 2.14 $ (23.80 )

Revenue from contracts with c_2

Revenue from contracts with customers (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of revenues by type of service	Schedule of revenues by type of service Three Months Ended Nine Months Ended 2024 2023 2024 2023 Product sales $ - $ 558,965 $ 169,373 $ 1,409,534 Laboratory services - 47,135 26,776 112,810 Collaboration revenue - 92,922 - 826,257 Total revenue $ - $ 699,022 $ 196,149 $ 2,348,601
Schedule of revenues by geography	Schedule of revenues by geography Three Months Ended Nine Months Ended 2024 2023 2024 2023 Domestic $ - $ 142,716 $ 196,149 $ 523,978 International - 556,306 - 1,824,623 Total revenue $ - $ 699,022 $ 196,149 $ 2,348,601
Schedule of changes in deferred revenue	Schedule of changes in deferred revenue Balance at December 31, 2022 $ 142,061 Contracts with customers 74,109 Recognized in the current period (144,196 ) Currency translation adjustment (46,048 ) Balance at December 31, 2023 25,926 Recognized in the current period (21,096 ) Refunded to customers in the current period (4,830 ) Balance at September 30, 2024 $ -

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of EIB loan guaranty	Schedule of EIB loan guaranty September 30, 2024 December 31, EIB $ - $ 10,873,867 Total obligations - 10,873,867 Unamortized discount - - Carrying value of EIB loan guaranty - 10,873,867 Less EIB loan guaranty (current portion) - (10,873,867 ) Long-term EIB loan guaranty $ - $ -

Stockholders_ equity (Tables)

Stockholders’ equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of company recognized stock compensation expense	Schedule of company recognized stock compensation expense Three months ended Nine months ended 2024 2023 2024 2023 Cost of services $ - $ (442 ) $ - $ (442 ) Research and development - (159,742 ) 48,820 (41,914 ) General and administrative 1,530 74,411 504,941 259,452 Sales and marketing - (143,710 ) 4,397 (78,928 ) $ 1,530 $ (229,483 ) $ 558,158 $ 138,168
Schedule of stock purchase warrants	Schedule of stock purchase warrants Outstanding at Issuance Exercise Price Expiration September 30, December 31, February 2015 $ 660,000.00 February 2025 3 3 October 2019 $ 400.00 October 2024 1,770 1,770 October 2019 $ 520.00 October 2024 1,175 1,175 November 2020 $ 504.40 May 2026 1,211 1,211 February 2021 $ 780.00 August 2026 2,084 2,084 May 2023 $ 7.785 (1) 889,274 889,274 October 2023 $ 3.36 April 2029 200,000 200,000 1,095,517 1,095,517 The warrants listed above were issued in connection with various equity, debt, or development contract agreements. (1) Warrants will be exercisable beginning on the date of stockholder approval of the exercisability of the warrants under Nasdaq rules. Once exercisable, the warrants will expire on the five-year anniversary of the date of such stockholder approval.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of ROU asset and liability classifications	Schedule of ROU asset and liability classifications Lease Classification September 30, December 31, ROU Assets: Operating $ 832,966 $ - Financing - 138 Total ROU assets $ 832,966 $ 138 Liabilities Current: Operating $ 167,021 $ 147,943 Finance - 280 Noncurrent: Operating 1,893,794 2,021,616 Finance - - Total lease liabilities $ 2,060,815 $ 2,169,839
Schedule of maturities of lease liabilities	Schedule of maturities of lease liabilities Maturity of Lease Liabilities Operating Finance Total 2024 (October to December) $ 90,395 $ - $ 90,395 2025 368,179 - 368,179 2026 378,279 - 378,279 2027 388,682 - 388,682 2028 399,388 - 399,388 Thereafter 1,338,299 - 1,338,299 Total lease payments 2,963,222 - 2,963,222 Less: Interest (902,407 ) - (902,407 ) Present value of lease liabilities $ 2,060,815 $ - $ 2,060,815
Schedule of lease cost	Schedule of lease cost Three months ended Nine months ended Lease Cost Classification 2024 2023 2024 2023 Operating Operating expenses $ 58,496 $ 175,243 $ 175,488 $ 484,546 Finance: Amortization Operating expenses - 847 138 2,514 Interest expense Other expenses - - - - Total lease costs $ 58,496 $ 176,090 $ 175,626 $ 487,060
Schedule of other information	Schedule of other information Other Information Total Weighted average remaining lease term (in years) Operating leases 7.4 Finance leases - Weighted average discount rate: Operating leases 10.0 % Finance leases - %
Schedule of supplemental cash flow information	Schedule of supplemental cash flow information Supplemental Cash Flow Information 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Cash used in operating activities Operating leases $ 175,488 $ 484,546 Finance leases $ - $ - Cash used in financing activities Finance leases $ 280 $ 2,523 ROU assets obtained in exchange for lease obligations: Operating leases $ - $ 801,321

Organization (Details Narrative

Organization (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Aug. 31, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Jul. 31, 2024	Apr. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Financing proceeds			$ 5,000	$ 13,300
Series E Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold		200,000			550,000	350,000
Additional funds	$ 2,450
Additional shares sold	2,450,000
Preferred stock, shares outstanding			0
March 2024 Purchase Agreement [Member] | Series E Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares converted	3,000,000
Number of shares issued	7,200,000
March 2024 Purchase Agreement [Member] | David E. Lazar [Member] | Series E Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (preferred shares)		3,000,000
Share price		$ 1
Financing proceeds		$ 3,000

Going Concern and Management__2

Going Concern and Management’s Plans (Details Narrative) - USD ($)		9 Months Ended
	Jun. 05, 2024	Sep. 30, 2024	Sep. 30, 2023	Oct. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Financing proceeds		$ 5,000,000	$ 13,300,000
Cash and cash equivalents		$ 1,633,166			$ 1,151,823
Common stock, par value (in Dollars per share)		$ 0.01			$ 0.01
Nasdaq Stockholders' Equity Rule, minimum balance	$ 2,500,000
A E I Capital Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock sold		1,079,109
Gross proceeds from common stock		$ 2,000,000
Common stock, par value (in Dollars per share)		$ 0.01
Additional aggregate value		$ 7,000,000
A E I Capital Ltd [Member] | August 2024 Securities Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate amount				$ 9,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,633,166	$ 1,151,823
Restricted cash	302,262	302,262
Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$ 1,935,428	$ 1,454,085

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Finished goods	$ 1,225,975	$ 1,280,805
Total, gross	1,225,975	1,280,805
Less inventory reserve	(1,225,975)	(1,280,805)
Total, net of inventory reserve

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Net income (loss)	$ 8,931,078	$ (4,062,957)	$ 7,642,696	$ (15,626,883)
Net income allocated to preferred stockholders	(690,467)		(519,161)
Net income (loss) available to common stockholders, basic	8,240,611	(4,062,957)	7,123,535	(15,626,883)
Net income (loss) available to common stockholders, diluted	$ 8,931,078	$ (4,062,957)	$ 7,642,696	$ (15,626,883)
Basic weighted average shares outstanding	5,760,214	877,815	2,837,744	656,585
Dilutive effect of preferred stock	$ 843,590		$ 733,761
Dilutive weighted average shares outstanding	6,603,804	877,815	3,571,505	656,585
Earnings (loss) per share, basic	$ 1.43	$ (4.63)	$ 2.51	$ (23.80)
Earnings (loss) per share, diluted	$ 1.35	$ (4.63)	$ 2.14	$ (23.80)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($) shares in Millions	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Adjustment to decrease preferred stock		$ 2,500
Increase additional paid-in capital		2,500
Accumulated other comprehensive loss		75,100
Loss on deconsolidation		75,138
Incremental loss		100,000
FDIC limit of insurable cash		250,000
Restricted cash		302,262		$ 302,262
Allowance for doubtful accounts receivable		0		0
Inventory		1,225,975		1,280,805
Impairment charge on ROU Assets		0	0
Amortization of intangible assets		0	187,255
Reduction in Research and Development Expense from Government Grant	$ 78,752		$ 301,229
Grants		$ 0
Tax benefit percentage		50%
Operating loss carryforwards				$ 241,110,447	$ 232,682,072
Number of anti dilutive shares excluded from earnings per share (in shares)		1.2	1.1
One Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage		92%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				39%
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	21%	48%	28%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				26%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	15%	14%	17%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				10%
Customer Three [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	12%		10%
Customer Four [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	11%
Minimum [Member]
Product Information [Line Items]
Accounts receivable period due		30 days
Maximum [Member]
Product Information [Line Items]
Accounts receivable period due		90 days

Revenue from contracts with c_3

Revenue from contracts with customers (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues		$ 699,022	$ 196,149	$ 2,348,601
Product [Member]
Disaggregation of Revenue [Line Items]
Revenues		558,965	169,373	1,409,534
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues		47,135	26,776	112,810
Collaborations Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 92,922		$ 826,257

Revenue from contracts with c_4

Revenue from contracts with customers (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues		$ 699,022	$ 196,149	$ 2,348,601
Domestic [Member]
Disaggregation of Revenue [Line Items]
Revenues		142,716	196,149	523,978
International [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 556,306		$ 1,824,623

Revenue from contracts with c_5

Revenue from contracts with customers (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Balance at beginning	$ 25,926	$ 142,061
Contracts with customers		74,109
Recognized in the current period	(21,096)	(144,196)
Currency translation adjustment		(46,048)
Refunded to customers in the current period	(4,830)
Balance at ending		$ 25,926

Fair value measurements (Detail

Fair value measurements (Details Narrative) € in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Aug. 19, 2024 USD ($)	May 31, 2022	Jun. 30, 2019 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2016 EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on extinguishment of debt | $				$ 9,738,487		$ 9,738,487
European Investment Bank [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on extinguishment of debt | $	$ 9,700,000
European Investment Bank [Member] | Fair Value, Recurring [Member] | Curetis Gmb H [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Drew down amount			€ 5
Curetis Gmb H [Member] | European Investment Bank [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Drew down amount			€ 5
Participation percentage interest			2.10%
Curetis Gmb H [Member] | European Investment Bank [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unsecured loan financing facility								€ 25
Additional payment percentage			2.10%
Curetis Gmb H [Member] | European Investment Bank [Member] | Fair Value, Recurring [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Drew down amount			€ 5
Participation percentage interest			2.10%
Curetis Gmb H [Member] | European Investment Bank [Member] | Fair Value, Recurring [Member] | Minimum [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
EIB waived for curetis to have equity capital raised to disburse the third tranche			€ 15
Op Gens Equity [Member] | European Investment Bank [Member] | Fair Value, Recurring [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Participation percentage interest		0.75%	0.30%
Maturity period		the Company entered into a Waiver and Amendment Letter which increased the PPI to 0.75% upon maturity.

Debt (Details)

Debt (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Total obligations		$ 10,873,867
Unamortized discount
Carrying value of EIB loan guaranty		10,873,867
Less EIB loan guaranty (current portion)		(10,873,867)
Long-term EIB loan guaranty
EIB [Member]
Short-Term Debt [Line Items]
Total obligations		$ 10,873,867

Debt (Details Narrative)

Debt (Details Narrative) € in Millions	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2024 USD ($)	Jun. 30, 2023 EUR (€)	May 31, 2022 EUR (€)	Jun. 30, 2019 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2016 EUR (€)	Jun. 30, 2018 EUR (€)	Apr. 30, 2017 EUR (€)
Short-Term Debt [Line Items]
Interest rate payable											4%
Interest rate	7.75%
Disburse tranche amount				€ 5
Indebtedness amount				€ 5
Total debt borrowed | $	$ 300,926
Repaid amount | $								$ 3,910,010
Monthly loan payment	$ 31,172		€ 0.7
Aggrement Amount Paid		€ 1
Total interest expense | $					$ 3,238	$ 396,768	4,317	$ 1,698,564
Share-Based Payment Arrangement, Tranche Two [Member]
Short-Term Debt [Line Items]
Indebtedness amount		€ 3	3
Share-Based Payment Arrangement, Tranche Three [Member]
Short-Term Debt [Line Items]
Indebtedness amount			5
Curetis NVs Equity [Member]
Short-Term Debt [Line Items]
Percentage of participation percentage interest				2.10%
EIB [Member]
Short-Term Debt [Line Items]
Maximum of unsecured loan financing facility									€ 25
Fund drawn period									36 months
Debt term									5 years
EIB waived for curetis to have equity capital raised to disburse the third tranche				€ 15
Extinguishment of debt | $							9,700,000
EIB [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Short-Term Debt [Line Items]
Accumulated and deferred interest			13.4
Repaid amount			5
EIB [Member] | First Tranche [Member]
Short-Term Debt [Line Items]
Unsecured debt											€ 10
Interest rate											6%
Total debt borrowed			€ 18
EIB [Member] | Second Tranche [Member]
Short-Term Debt [Line Items]
Unsecured debt										€ 3
EIB [Member] | Third Tranche [Member]
Short-Term Debt [Line Items]
Unsecured debt				€ 5
EIB [Member] | Op Gens Equity Value [Member]
Short-Term Debt [Line Items]
Percentage of participation percentage interest				0.30%
PPI [Member]
Short-Term Debt [Line Items]
Percentage of participation percentage interest				2.10%
PPI [Member] | Minimum [Member]
Short-Term Debt [Line Items]
PPI of OPGEN amended, percentage			0.30%
PPI [Member] | Maximum [Member]
Short-Term Debt [Line Items]
PPI of OPGEN amended, percentage			0.75%
EIB Debt Financing Facility [Member]
Short-Term Debt [Line Items]
Fair value of the EIB debt | $					$ 15,800,000		$ 15,800,000

Stockholders equity (Details)

Stockholders equity (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based compensation expense	$ 1,530	$ (229,483)	$ 558,158	$ 138,168
Cost of Sales [Member]
Share-based compensation expense		(442)		(442)
Research and Development Expense [Member]
Share-based compensation expense		(159,742)	48,820	(41,914)
General and Administrative Expense [Member]
Share-based compensation expense	1,530	74,411	504,941	259,452
Selling and Marketing Expense [Member]
Share-based compensation expense		$ (143,710)	$ 4,397	$ (78,928)

Stockholders equity (Details 1)

Stockholders equity (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	May 31, 2023
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)			$ 7.785
Shares of Common Stock Subject to Warrants	1,095,517	1,095,517
February 2015 [Member] | Warrants Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 660,000
Expiration	February 2025
Shares of Common Stock Subject to Warrants	3	3
October 2019 [Member] | Warrant Exercise Price Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 400
Expiration	October 2024
Shares of Common Stock Subject to Warrants	1,770	1,770
October 2019 [Member] | Warrants Exercise Price Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 520
Expiration	October 2024
Shares of Common Stock Subject to Warrants	1,175	1,175
November 2020 [Member] | Warrants Exercise Price Ten [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 504.40
Expiration	May 2026
Shares of Common Stock Subject to Warrants	1,211	1,211
February 2021 [Member] | Warrants Exercise Price Seven [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 780
Expiration	August 2026
Shares of Common Stock Subject to Warrants	2,084	2,084
May 2023 [Member] | Warrant Exercise Price Nine [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 7.785
Shares of Common Stock Subject to Warrants	889,274	889,274
October 2023 [Member] | Warrant Exercise Price Ten [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 3.36
Expiration	April 2029
Shares of Common Stock Subject to Warrants	200,000	200,000

Stockholders_ equity (Details N

Stockholders’ equity (Details Narrative) - USD ($)		1 Months Ended					3 Months Ended	9 Months Ended
	Oct. 11, 2023	Aug. 31, 2024	Mar. 31, 2024	Oct. 31, 2023	May 31, 2023	Jan. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Oct. 31, 2024	Jul. 31, 2024	Jun. 30, 2024	Apr. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Common stock issued					60,500		10,068,111	10,068,111						1,282,686
Common stock, shares outstanding							10,068,111	10,068,111						1,282,686
Preferred Stock, shares authorized							10,000,000	10,000,000
Preferred stock shares unissued							6,999,000	6,999,000
Preferred stock, share undesignated							6,999,000	6,999,000
Exercise price of common warrants (in Dollars per share)					$ 7.785	$ 26.50
Exercise price per share (in Dollars per share)						$ 0.10
Exercise price per share					7.785
Common stock par value per share				$ 0.01	$ 0.01
Pre-funded warrants					389,083
Common warrants issued					449,583
Price per share of common stock and accompanying common warrant (in Dollars per share)					$ 7.785
Price per share of pre-funded warrant and common warrants (in Dollars per share)					$ 7.685
Gross Proceeds from Equity Transaction					$ 3,500,000
Net proceeds (in Dollars)					$ 3,000,000
Number of repriced warrants to purchase shares					639,691
Additional paid capital												$ 300,000
Number of warrants exercised (in Shares)				200,000
Gross proceeds for the warrant inducement (in Dollars)				$ 2,057,000
Price per share of Series D Preferred Stock				$ 1,000
Price per share	$ 4.09
Affiliates holding percentage	19.99%
Warrants available for inducement (in shares)				1,089,274
Exercise prices				$ 7.785
Additional consideration required per share				$ 0.25
Common stock percentage				100%
Common stock, par value (in Dollars per share)							$ 0.01	$ 0.01						$ 0.01
Shares issued price								$ 3,000,000
Proceeds from common stock									$ 10,188,158
Number of options, expired							5,813	8,594
Restricted stock units outstanding							4,163	4,163
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of options, forfeited							0	4,163
Number of options, granted							0	61,053
Number of options, vested								61,053
Equity Option [Member]
Class of Stock [Line Items]
Stock option outstanding							138	138
Options Held [Member]
Class of Stock [Line Items]
Number of options, forfeited							0	892
Two Thousand Fifteen Plan [Member]
Class of Stock [Line Items]
Stock option description								In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Shares added							48,058	48,058
Remaining shares							12,506	12,506
A E I Capital Ltd [Member]
Class of Stock [Line Items]
Common stock, par value (in Dollars per share)							$ 0.01	$ 0.01
Number of common stock sold								1,079,109
Proceeds from common stock								$ 2,000,000
A E I Capital Ltd [Member] | August 2024 Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Aggregate amount										$ 9,000,000
Minimum [Member]
Class of Stock [Line Items]
Minimum warrant exercise price from prior offerings (in Dollars per share)					$ 26.50
Maximum [Member]
Class of Stock [Line Items]
Maximum warrant exercise price from prior offerings (in Dollars per share)					75.40
Common Stock [Member]
Class of Stock [Line Items]
Common stock par value per share					0.10
Additional consideration exercise price (in Dollars per share)					$ 0.25
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Prefunded warrants						226,500
Prefunded Warrants Offering Price Per Share (in Dollars per share)						$ 28.90
Securities Purchase Agreement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Price per share of common stock and common warrant (in Dollars per share)						$ 29
Securities Purchase Agreement [Member] | Common Warrants Issued
Class of Stock [Line Items]
Gross proceeds (in Dollars)						$ 7,500,000
Net proceeds (in Dollars)						$ 6,900,000
Series A1 Common Warrants [Member]
Class of Stock [Line Items]
Aggregate warrants						258,621
Series A2 Common Warrants [Member]
Class of Stock [Line Items]
Aggregate warrants						258,621
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Price per share of Series D Preferred Stock				$ 1,000
Preferred Stock, par value				$ 0.01
Series D Preferred Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Consideration paid				$ 250,000
Additional consideration required				$ 750,000
Series E Preferred Stock [Member] | March 2024 Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares converted		3,000,000
Number of shares issued		7,200,000
Series E Preferred Stock [Member] | David E. Lazar [Member] | March 2024 Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of stock description			In March 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions under the March 2024 Purchase Agreement in exchange for 200,000 shares of Series E Preferred Stock. Mr. Lazar subsequently paid $350,000 in exchange for an additional 350,000 shares of Series E Preferred Stock in April 2024.
Conversion basis			Each share of Series E Preferred Stock was convertible into 2.4 shares of the Company’s common stock
Number of common stock sold			3,000,000
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Shares sold			200,000								550,000		350,000
Additional funds		$ 2,450,000
Additional shares		2,450,000
Preferred stock, shares outstanding							0	0

Leases (Details)

Leases (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
ROU Assets:
Operating	$ 832,966
Financing		138
Total ROU assets	832,966	138
Current:
Operating	167,021	147,943
Finance		280
Noncurrent:
Operating	1,893,794	2,021,616
Finance
Total lease liabilities	$ 2,060,815	$ 2,169,839

Leases (Details 1)

Leases (Details 1)	Sep. 30, 2024 USD ($)
Lessee, Lease, Description [Line Items]
2024 (October to December)	$ 90,395
2025	368,179
2026	378,279
2027	388,682
2028	399,388
Thereafter	1,338,299
Total lease payments	2,963,222
Less: Interest	(902,407)
Present value of lease liabilities	2,060,815
Operating [Member]
Lessee, Lease, Description [Line Items]
2024 (October to December)	90,395
2025	368,179
2026	378,279
2027	388,682
2028	399,388
Thereafter	1,338,299
Total lease payments	2,963,222
Less: Interest	(902,407)
Present value of lease liabilities	2,060,815
Finance [Member]
Lessee, Lease, Description [Line Items]
2024 (October to December)
2025
2026
2027
2028
Thereafter
Total lease payments
Less: Interest
Present value of lease liabilities

Leases (Details 2)

Leases (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lease, Cost	$ 58,496	$ 176,090	$ 175,626	$ 487,060
Operating Expense [Member]
Operating expenses	58,496	175,243	175,488	484,546
Finance Lease, Right-of-Use Asset, Amortization		847	138	2,514
Other Expense [Member]
Finance Lease, Interest Expense

Leases (Details 3)

Leases (Details 3)	Sep. 30, 2024
Leases
Operating leases	7 years 4 months 24 days
Operating leases	10%
Finance leases

Leases (Details 4)

Leases (Details 4) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash used in operating activities
Operating leases	$ 175,488	$ 484,546
Finance leases
Cash used in financing activities
Finance leases	280	2,523
ROU assets obtained in exchange for lease obligations:
Operating leases		$ 801,321

License agreements, research _2

License agreements, research collaborations and development agreements (Details Narrative) € in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2022 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Qiagen [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual agreement period				20 years
Contractual days				180 days
Siemens [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expenses		$ 0	$ 3,102	$ 0	$ 7,309
Siemens [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate				1.30%
Siemens [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate				40%
Curetis GmbH And FIND [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement proceeds (in Euro) | €	€ 0.7
Contract to Date Proceeds (in dollars)				$ 900,000